Portage Biotech (NASDAQ:PRTG – Get Rating) had its price target reduced by HC Wainwright from $32.00 to $22.00 in a report released on Tuesday, The Fly reports. They currently have a buy rating on the stock.
Separately, Oppenheimer initiated coverage on Portage Biotech in a report on Friday, July 15th. They set a buy rating and a $26.00 price target for the company.
Portage Biotech Price Performance
Shares of PRTG opened at $7.71 on Tuesday. Portage Biotech has a one year low of $4.62 and a one year high of $23.99. The firm has a market capitalization of $130.65 million, a P/E ratio of -6.65 and a beta of 1.81. The business has a fifty day moving average of $8.62 and a 200 day moving average of $7.84.
Hedge Funds Weigh In On Portage Biotech
Hedge funds have recently made changes to their positions in the business. Allspring Global Investments Holdings LLC bought a new position in shares of Portage Biotech in the first quarter worth about $53,000. Sigma Planning Corp bought a new position in shares of Portage Biotech in the first quarter worth about $75,000. Goldman Sachs Group Inc. bought a new position in shares of Portage Biotech in the second quarter worth about $79,000. Beacon Investment Advisory Services Inc. bought a new position in shares of Portage Biotech in the second quarter worth about $80,000. Finally, Millennium Management LLC bought a new position in shares of Portage Biotech in the second quarter worth about $92,000. Institutional investors own 0.97% of the company’s stock.
About Portage Biotech
Portage Biotech Inc, together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury.
- Get a free copy of the StockNews.com research report on Portage Biotech (PRTG)
- 3 Airline Stocks Stuck in a Holding Pattern
- Roku Stock is Down but Not Out
- If You’re Hungry for Value, Take a Bite on Ruth’s Hospitality Grp
- Is Ford Rolling To A Rebound After Its Q3 Warning
- Has AMD stock stock fallen too far?
Receive News & Ratings for Portage Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portage Biotech and related companies with MarketBeat.com's FREE daily email newsletter.